Summary of the National Advisory Committee on Immunization (NACI) Supplemental Statement on Recombinant Influenza Vaccines

CONCLUSION: There is fair evidence that Supemtek is effective, safe, and has non-inferior immunogenicity to comparable vaccines, based on direct evidence in adults 18 years of age and older; thus, NACI recommends that Supemtek may be considered among the seasonal influenza vaccines offered to adults 18 years of age and older for their annual influenza vaccination.PMID:38116047 | PMC:PMC10729781

Source: Can Commun Dis Rep - December 20, 2023 Category: Infectious Diseases Authors: Anabel Gil Angela Sinilaite Jesse Papenburg Source Type: research